TIDES Europe 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

CMC and manufacturing at TIDES Europe 2026

Nov 3–5, 2026 Amsterdam, Netherlands ~900 attendees Website

59 organizations at TIDES Europe 2026 present work in CMC & manufacturing: 43 suppliers and service providers, 12 drug developers and 4 academic, government and non-profit bodies. Between them they bring 89 presentations to the program. Most represented: Novo Nordisk (6 on the program), Bachem (5 on the program), Roche (5 on the program). As of Nov 2, 2026.

All 167 organizations at TIDES Europe 2026 →

Format
Top represented
Showing 1–9 of 59 organizations
OrganizationTIDES Europe 2026 Attendance
Novo Nordisk
Bagsværd, Denmark
Large pharma
Danish pharmaceutical company known for diabetes and obesity medicines, including the GLP-1 peptide drugs semaglutide and liraglutide.
Keynote
Tue Nov 3
13:50–14:25
Next Generation GLP-1 Therapeutics
How GLP-1 drugs for metabolic disease became longer-acting, and what it would take to dose them less often or swallow them as pills.
PeptidesObesity & Metabolic
Talk
Wed Nov 4
08:05–08:35
Shifting Landscape: Global Regulatory CMC Guidance for Synthetic Oligonucleotides
Where regulators around the world now agree and disagree on manufacturing and quality rules for synthetic oligonucleotides, and how those rules could align.
with Roche
Talk
Thu Nov 5
09:05–09:35
Identity Testing of Synthetic Peptides: From Multi-Method Evaluation to a Compliant Two-Test Scheme
Why two well-chosen laboratory tests can prove a manufactured peptide is the intended molecule, rather than the longer list of tests regulators expect.
Talk
Thu Nov 5
08:35–09:05
siRNA Conjugate Mediated Delivery to Disease Specific Cell Types Occurs through a Novel Mechanism
How siRNA drugs attached to a carrier reach the cells behind chronic inflammatory disease and cancer, and how that route was worked out.
Talk
Fri Nov 6
09:10–10:00
Keynote Panel: From Lab to Launch - Navigating the European Obesity Therapeutics Landscape
What it takes to turn obesity research into a product Europe will approve, manufacture at scale and actually pay for.
Post-event symposium · with Cantoni Therapeutics, Aphaia Pharma, Constructive Bio
Talk
Fri Nov 6
08:40–09:10
Keynote Presentation: Decoding The Future of Obesity Care: The Signals Worth Paying Attention To
Where obesity drug development stands in 2026 and which companies and market openings across Europe are worth watching.
Post-event symposium
Talk
Fri Nov 6
11:40–12:05
Presentation: Energy Expenditure Modulation as an Emerging Therapeutic Strategy for Obesity
Post-event symposium: Clinical & Translational Updates
Bachem
Bubendorf, Switzerland
CDMO & CROPlatinum sponsor
Contract development and manufacturing organization for peptide and oligonucleotide active pharmaceutical ingredients, from research quantities to commercial scale.
Booth
Exhibiting at Booth 703
Tue, Nov 33:00pm–6:30pmWed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm
Talk
Wed Nov 4
14:30–15:00
Beyond Packed Beds: Advancing Scalable Oligonucleotide Manufacturing Through Stirred-Bed Technology
Building oligonucleotides in a continuously stirred reactor rather than a packed column, so reagents mix evenly and batches can reach ton scale.
Talk
Wed Nov 4
16:15–16:45
Dapiglutide: From Lab to Large Scale Manufacture through Innovative Peptide Process Development
How process changes in making the peptide drug dapiglutide raised its overall yield from about 20% to over 60%.
with Zealand Pharma
Talk
Wed Nov 4
15:00–15:30
Dehydroascorbate: More Sustainable Disulfide Bond Formation in Peptide Manufacturing
Using an oxidised form of vitamin C instead of harsh chemicals to form the sulfur bridges that hold many peptide drugs in shape.
Talk
Wed Nov 4
11:50–12:20
Digital Manufacturing in Practice: Enabling Efficient and Compliant Large-scale Production
Running large-scale production on digital records and automation, and what that changed for output, consistency and the ability to spot process problems.
CMC & Manufacturing
Chair
Thu Nov 5
08:00–08:05
Chairman’s Remarks: Innovations in Peptide CMC
Peptide Discovery to CMC
Roche
Basel, Switzerland
Large pharma
Swiss pharmaceutical and diagnostics company with oligonucleotide and peptide programmes in its drug pipeline.
Chair
Wed Nov 4
08:00–08:05
Chairperson’s Remarks: Regulatory CMC Strategies for Oligonucleotides
Oligonucleotide Chemistry, Manufacturing & Controls
Talk
Wed Nov 4
14:00–14:30
Enzymatic Ligation for the Production of Oligonucleotides
Screening many ways to cut and rejoin siRNA strands with enzymes, then scaling the best one up for cleaner, higher-yield production.
Talk
Wed Nov 4
08:05–08:35
Shifting Landscape: Global Regulatory CMC Guidance for Synthetic Oligonucleotides
Where regulators around the world now agree and disagree on manufacturing and quality rules for synthetic oligonucleotides, and how those rules could align.
with Novo Nordisk
Talk
Thu Nov 5
10:45–11:15
MCSGP Process Control and Characterization Strategy
Keeping a multi-column peptide purification system dependable by working out which settings must stay within range to hold purity steady at full scale.
Talk
Thu Nov 5
11:15–11:45
Regulatory Insights from Recent Global Phase 3 Peptide Filings
What health authorities asked about manufacturing, quality control and delivery devices during recent late-stage applications for peptide drugs.
Eli Lilly and Company
Indianapolis, IN
Large pharma
Global pharmaceutical company whose peptide medicines include tirzepatide, with programs in oligonucleotide therapeutics.
Keynote
Tue Nov 3
13:15–13:50
Making Oligonucleotides a High-Volume Reality: Next-Gen Platforms and Strategy for Oligonucleotide Manufacturing
Keynote Sessions - MAIN CONFERENCE
OligonucleotidesCMC & Manufacturing
Keynote
Tue Nov 3
14:25–15:00
Retatrutide: From Breakthrough Science to Global Medicine — The CMC Story Behind a Novel GIP, GLP-1, and Glucagon Receptor Agonist
How the obesity and diabetes drug retatrutide is made at world supply scale by joining peptide fragments in solution with far less waste.
PeptidesCMC & Manufacturing
Talk
Wed Nov 4
16:45–17:15
Made to Scale: What Tirzepatide's Manufacturing Challenge Teaches Us About Innovation Under Pressure
Lessons from scaling up production of the diabetes and obesity drug tirzepatide, from an odd result at the bench to tonnes of material.
Chair
Thu Nov 5
08:00–08:05
Chairpersons Remarks: Targeted Delivery of Oligonucleotides
Oligonucleotide Discovery, Preclinical and Clinical
Talk
Thu Nov 5
16:00–16:30
Cycle Time Is a Quality Metric: Eloralintide from Discovery to Clinical Proof of Concept
How the peptide eloralintide moved from discovery into patients by overlapping chemistry and biology cycles instead of running them one after another.
AstraZeneca
Cambridge, United Kingdom
Large pharma
Global pharmaceutical company developing medicines across modalities, including oligonucleotide and peptide therapeutics.
Talk
Thu Nov 5
15:00–15:30
Maintaining Diastereomeric Control in Phosphorothioate siRNAs: Integrated Analytical and Manufacturing Approaches for Reliable Clinical Development
Why purifying siRNA can quietly shift the mix of mirror-image sulfur linkages between batches, and how to keep that mix steady.
Talk
Thu Nov 5
09:05–09:35
Peptide-Targeted Delivery of Oligonucleotide Therapeutics
Early, pre-clinical work on a short peptide that steers gene-silencing drugs into the tissue where they are meant to act.
Talk
Thu Nov 5
09:05–09:35
Rethinking Green Credentials for Oligo Manufacturing
Why simple waste-per-kilogram scores misjudge how green oligonucleotide production is, and what real improvement would involve.
Talk
Thu Nov 5
08:35–09:05
Systematic Route Design for Fragment-Based Peptide Synthesis: Enabling Liquid-Phase Transition
A way to choose where to split a long peptide into fragments so it can be built in solution with better yield.
PolyPeptide Group
Baar, Switzerland
CDMO & CROSilver sponsor
Contract development and manufacturing organization for peptide and oligonucleotide APIs, from clinical to commercial scale.
Booth
Exhibiting at Booth 309
Tue, Nov 33:00pm–6:30pmWed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm
Talk
Tue Nov 3
09:05–09:35
Strategies for Manufacturing of Long and Complex Peptides: Technical Considerations and Case Studies
Ways to make long, sticky peptides at scale by mixing solid-support and solution methods and cutting solvent use, with real examples.
Talk
Wed Nov 4
14:00–14:30
Case Studies of Pre-clinical Development and IND Acceleration for Peptides
Case studies on lining up early peptide process work, manufacturing plans and safety testing so a drug reaches first clinical trials sooner.
Codexis
Redwood City, CA
Materials & equipmentSilver sponsor
Engineers enzymes and the ECO Synthesis enzymatic platform for manufacturing siRNA and other RNA therapeutics.
Booth
Exhibiting at Booth 508
Tue, Nov 33:00pm–6:30pmWed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm
Talk
Wed Nov 4
15:00–15:30
Advancing siRNA Manufacturing at Scale and with User-Defined Phosphorothioate Stereochemistry
How an enzyme-based process controls the mirror-image shape of sulfur-containing backbone links in siRNA, now made at the 100-gram scale.
Talk
Wed Nov 4
09:45–09:55
Delivering Scalable siRNA Therapeutics Sustainably
How an enzyme-based way of making siRNA drugs is scaling up, recently reaching 100 grams, while using less solvent.
OligonucleotidesCMC & Manufacturing
Axolabs
Kulmbach, Germany
CDMO & CROPlatinum sponsor
Oligonucleotide contract research and manufacturing organization offering discovery, preclinical, analytical and GMP manufacturing services.
Booth
Exhibiting at Booth 515
Tue, Nov 33:00pm–6:30pmWed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm
Talk
Tue Nov 3
09:05–09:45
Rethinking Oligonucleotide Manufacturing: Economics, Sustainability and Regulatory Considerations Across Four Manufacturing Platforms
Workshop #1:CMC Decisions That Influence Cost of Goods (COGs) in Oligo Scale-up: Levers for Scientific and Commercial Impact
Chair
Tue Nov 3
09:00–09:05
Workshop Moderators’ Introduction
Which early manufacturing and quality decisions set what an oligonucleotide drug costs to produce, and when in development they should be taken.
with Livinovea
Talk
Wed Nov 4
13:25–13:55
From Development Candidate Nomination to First-in-Human: Accelerating Oligonucleotide Development Through Integrated Strategies
What it took to move a sugar-tagged siRNA candidate from selection to its first human trial on a tight schedule.
OligonucleotidesCMC & Manufacturing
Biogen
Cambridge, MA
Large pharma
Biopharmaceutical company developing and marketing neuroscience medicines, including antisense oligonucleotide treatments.
Talk
Tue Nov 3
10:45–11:00
Balancing Cost, Productivity, and Safety in ASO Manufacturing
Workshop #1:CMC Decisions That Influence Cost of Goods (COGs) in Oligo Scale-up: Levers for Scientific and Commercial Impact
Talk
Wed Nov 4
10:15–10:45
Finding the Right Balance: How Formulation Aspects and Regulatory Expectations Affect Steam Sterilization of Antisense Oligonucleotide (ASO) Drug Products
Whether antisense drug products can survive steam sterilisation, and how the liquid formula and container can be tuned so regulators accept it.
Talk
Thu Nov 5
08:05–08:35
Strategies for Implementing a Comprehensive Impurity Control Approach Across Oligonucleotide Purification Process
A risk-based plan for clearing unwanted by-products, solvents and bacterial toxins from an oligonucleotide drug during two purification steps and filtration.

Explore the full TIDES Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Amsterdam. Leave your work email and we’ll be in touch.

Privacy

Download the full TIDES Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers in CMC & manufacturing

Tell us what you sell and we’ll find the people at organizations working on CMC & manufacturing most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse TIDES Europe 2026 by

Exhibit hall

Not affiliated with or endorsed by TIDES Europe or its organizers. Submit a correction